Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing

Modern Pathology

Volumn 27, Issue 11, 2014, Pages 1438-1446

  Salipante, Stephen J ^a   Fromm, Jonathan R ^a   Shendure, Jay ^a   Wood, Brent L ^a   Wu, David ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

acute myeloid leukemia; minimal residual disease; next generation sequencing; NPM1; prognosis; relapse; tumor heterogeneity

Indexed keywords

NUCLEOPHOSMIN; NUCLEAR PROTEIN; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ARTICLE; B LYMPHOCYTE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; FLOW CYTOMETRY; GENE INSERTION; HUMAN; IMMUNOPHENOTYPING; LIMIT OF DETECTION; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; COMPARATIVE STUDY; EXON; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; EXONS; FLOW CYTOMETRY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926148720     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.57     Document Type: Article

References (40)

1. Bacher U, Badbaran A, Fehse B, et al. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allo-geneic stem cell transplantation. Exp Hematol 2009; 37:135-1342.
2. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allo-geneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122:1813-1821.
3. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011;29: 1190-1197.
4. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220-2231.
5. Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104:3078-3085.
6. Wood BL. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol 2013; 999:123-136.
7. Voskova D, Schoch C, Schnittger S, et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorpho-logic, cytogenetic, and molecular genetic findings. Cytometry B 2004;62:25-38.
8. Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117:1109-1120.
9. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-266.
10. Pritchard CC, Salipante SJ, Koehler K, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 2014;16:56-67.
11. Thol F, Kolking B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer 2012; 51:689-695.
12. Wu D, Sherwood A, Fromm JR, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012;4: 134ra63.
13. Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120: 5173-5180.
14. Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in patients with B lympho-blastic leukemia by high-throughput sequencing of IGH. Submitted.
15. Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 2006;130: 680-690.
16. Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 2012;6: 1621-1624.
17. Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD. PANDAseq: paired-end assembler for illumina sequences. BMC Bioinform 2012;13:31.
18. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010;26:589-595.
19. Hiatt JB, Pritchard CC, Salipante SJ, O'Roak BJ, Shendure J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res 2013;23:843-854.
20. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22:568-576.
21. Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005;19:1760-1767.
22. Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011;29:2709-2716.
23. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106: 2854-2861.
24. Kronke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013;122:100-108.
25. Hafez M, Ye F, Jackson K, et al. Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations. J Mol Diagn 2010;12:629-635.
26. Shayegi N, Kramer M, Bornhauser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 2013;122:83-92.
27. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program 2012;2012:35-42.
28. Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2011;119:332-341.
29. Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE, Campana D. Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 2009;9(Suppl 3):S281-S285.
30. Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010;22:656-663.
31. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008;35:388-400.
32. Ley TJ, Minx PJ, Walter MJ, et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci USA 2003;100: 14275-14280.
33. Conte N, Varela I, Grove C, et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Leukemia 2013;27:1820-1825.
34. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066.
35. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150:264-278.
36. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-510.
37. Network TCGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-2074.
38. Harismendy O, Schwab RB, Bao L, et al. Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol 2011;12:R124.
39. Bochtler T, Stolzel F, Heilig CE, et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol 2013;31:3898-3905.
40. Alpermann T, Haferlach C, Dicker F, et al. Evaluation of different NPM1 mutations in AML patients according to clinical, cytogenetic and molecular features and impact on outcome. Blood 2013;122:51.